Emergent stops manufacturing at Baltimore facility after FDA inspection

Emergent BioSolutions (EBS) disclosed that it has entered into agreements related to the manufacturing of bulk drug substance for various COVID-19 vaccine candidates at its Bayview facility in Baltimore, Maryland. On April 12, the Food and Drug Administration initiated an inspection of the Bayview facility. On April 16, at the request of the FDA, Emergent agreed not to initiate the manufacturing of any new material at its Bayview facility and to quarantine existing material manufactured at the Bayview facility pending completion of the inspection and remediation of any resulting findings. Emergent has been producing materials for Johnson & Johnson’s (JNJ) and AstraZeneca’s (AZN) Covid vaccines at the Bayview facility.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire